1. The first biosimilar of Rituxan, called Truxima, was approved for the treatment of adult patients with non-Hodgkin lymphoma.
2. Xospata, which are tablets, treat adult patients who have acute myeloid leukemia with a certain genetic mutation or who were in remission and relapsed.
3. The FDA approved Firdapse, the first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder that affects the connection between nerves, causing weakness in affected patients.
4. Vitrakvi is an oncology drug that treats cancers that have a specific genetic feature, also known as a biomarker. It does not target a specific type of tumor like many cancer treatments.
5. ATCPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of moderate to severe rheumatoid arthritis.
More articles on supply chain:
What’s next? 5 predictions for the healthcare supply chain in 2019
Cleveland Clinic leads list of 25 top healthcare supply chains for 2018
Sales reps may get the boot from hospital ORs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
